Download PDF
Phlebologie 2016; 45(05): 333-340
DOI: 10.12687/phleb2339-5-2016
Eduction: in Pictures
Schattauer GmbH

Pyoderma gangraenosum – from the right diagnostic investigations to targeted therapy

Article in several languages: English | deutsch
F. Jockenhöfer
1   Clinic for Dermatology, Venerology and Allergology, Universitätsklinikum Essen/Germany
,
J. Dissemond
1   Clinic for Dermatology, Venerology and Allergology, Universitätsklinikum Essen/Germany
› Author Affiliations
Further Information

Publication History

Received: 19 September 2016

Accepted: 20 September 2016

Publication Date:
22 December 2017 (online)

    Permissions and Reprints

Summary

Pyoderma gangrenosum (PG) is a rarely diagnosed neutrophilic skin disorder that still remains a diagnosis of exclusion. Therefore, the diagnosis has to be done in the synopsis of typical clinical findings, patient’s history and exclusion of relevant differential diagnoses. There are numerous references to relevant comorbidities from the metabolic syndrome, rheumatoid arthritis and inflammatory bowel diseases. Of particular importance is the potential association of PG with (haematologic) neoplasms. Treatment of PG includes topical and systemic immuno-modulating or immuno-suppressant therapies. Most important are for topical as well as systemic treatments are glucocorticoids. All other treatments represent an off-label-use. Especially Cyclosporine and TNF-α-inhibitors demonstrated very good and promising clinical results. Accompanying modern moist wound-therapy concepts avoiding painful dressings and an analgesic therapy are recommended.

Keywords

Neutrophilic dermatosis - Pyoderma gangrenosum - pain - wounds - pathergy-phenomenon
 

  • Literatur

  • 1 Al Ghazal P, Dissemond J. Therapie des Pyoderma gangraenosum in Deutschland: Resultate einer Befragung von Experten. J Dtsch Dermatol Ges 13: 317-325.
    Google Scholar
  • 2 Al Ghazal P, Herberger K, Schaller J. et al. Multicentric analysis of associated factors and comorbidities in 259 patients with pyoderma gangrenosum in Germany. Orphanet J Rare Dis 2013; 08: 136.
    CrossrefPubMedGoogle Scholar
  • 3 Al Ghazal P, Klode J, Dissemond J. Diagnosekriterien des Pyoderma gangraenosum: Resultate einer Befragung dermatologischer Wundexperten in Deutschland. J Dtsch Dermatol Ges 2014; 12: 1129-1131.
    PubMedGoogle Scholar
  • 4 André MF, Piette JC, Kémény JL. et al. French Study Group on Aseptic Abscesses. Aseptic abscesses: a study of 30 patients with or without inflammatory bowel disease and review of the literature. Medicine (Baltimore) 2007; 86: 145-161.
    CrossrefPubMedGoogle Scholar
  • 5 Barbosa NS, Tolkachjov SN, El-Azhary RA, Davis MD, Camilleri MJ, McEvoy MT, Bridges AG, Wetter DA. Clinical features, causes, treatments, and outcomes of peristomal pyoderma gangrenosum (PPG) in 44 patients: The Mayo Clinic experience, 1996 through 2013. J Am Acad Dermatol. (in press).
    Google Scholar
  • 6 Bennett ML, Jackson JM, Jorizzo JL, Fleischer Jr AB, White WL, Callen JP. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 2000; 79: 37-46.
    CrossrefPubMedGoogle Scholar
  • 7 Binus AM, Qureshi AA, Li VW, Winterfield LS. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol 2011; 165: 1244-1250.
    CrossrefPubMedGoogle Scholar
  • 8 Brooklyn TN, Dunnill MGS, Shetty A, Bowden JJ, Williams JDL, Griffiths CEM, Forbes A, Greenwood R, Probert CS. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006; 55: 505-509.
    CrossrefPubMedGoogle Scholar
  • 9 Cosgarea I, Lovric Z, Körber A, Dissemond J. Successful treatment of refractory pyoderma gangrenosum with Ustekinumab only after excision of renal cell carcinoma. Int Wound J. (in press).
    Google Scholar
  • 10 De Fairweather L, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 2008; 173: 600-609.
    CrossrefPubMedGoogle Scholar
  • 11 Dissemond J. Differentialdiagnosen des Ulcus cruris venosum. Phlebologie 2011; 40: 85-92.
    Article in Thieme ConnectGoogle Scholar
  • 12 Dissemond J, Augustin M, Eming S, Goerge T, Horn T, Karrer S, Schumann H, Stücker M. für die Arbeitsgemeinschaft Wundheilung (AGW) der DDG. Moderne Wundtherapie – praktische Aspekte der lokalen, nicht-interventionellen Behandlung chronischer Wunden. J Dtsch Dermatol Ges 2014; 12: 541-554.
    CrossrefPubMedGoogle Scholar
  • 13 Dissemond J, Protz K, Reich-Schupke S, Stücker M, Kröger K. Kompressionstherapie bei Ulcus cruris. Hautarzt 2016; 67: 311-325.
    CrossrefPubMedGoogle Scholar
  • 14 Hadi A, Lebwohl M. Clinical features of pyoderma gangrenosum and current diagnostic trends. J Am Acad Dermatol 2011; 64: 950-954.
    CrossrefPubMedGoogle Scholar
  • 15 Herberger K, Dissemond J, Hohaus K, Schaller J, Anastasiadou Z, Augustin M. Treatment of pyoderma gangrenosum – retrospective multicenter analysis of 121 patients. Br J Dermatol. (in press).
    Google Scholar
  • 16 Huptas L, Rompoti N, Herbig S, Körber A, Klode J, Schadendorf D, Dissemond J. Schmerzreduktion bei Patienten mit chronischem Ulcus cruris durch ein neu entwickeltes Morphin-Gel: Erste Resultate einer klinischen Untersuchung. Hautarzt 2011; 62: 280-286.
    CrossrefPubMedGoogle Scholar
  • 17 Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the united states. Clin Immunol Immunopathol 1997; 84: 223-243.
    CrossrefPubMedGoogle Scholar
  • 18 Jockenhöfer F, Herberger K, Schaller J, Hohaus KC, Stoffels-Weindorf M, Al Ghazal P, Augustin M, Dissemond J. Trizentrische Analyse von Kofaktoren und Komorbiditäten des Pyoderma gangraenosum. J Dtsch Dermatol Ges. (in press).
    Google Scholar
  • 19 Jockenhöfer F, Klode J, Kröger K, Roesch A, Al Ghazal P, Dissemond J. Patients with pyoderma gangrenosum: Analyses of the German DRG-data from 2012. Int Wound J. (in press).
    Google Scholar
  • 20 Langan SM, Groves RW, Card TR, Gulliford MC. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: A retrospective cohort study. J Invest Dermatol 2013; 132: 2166-2170.
    Google Scholar
  • 21 Marzano AV, Borghi A, Meroni PL, Cugno M. Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br J Dermatol. (in press).
    Google Scholar
  • 22 Mlika RB, Riahi I, Fenniche S, Mokni M, Dhaoui MR, Dess N, Dhahri AB, Mokhtar I. Pyoderma gangrenosum: a report of 21 cases. Int J Dermatol 2002; 41: 65-68.
    CrossrefPubMedGoogle Scholar
  • 23 Moroni L, Bianchi I, Lleo A. Geoepidemiology, gender and autoimmune disease. Autoimmun Rev 2012; 11: 386-392.
    CrossrefPubMedGoogle Scholar
  • 24 Müller-Ladner U, Alten R, Heiligenhaus A, Kekow J, Koletzko S, Mrowietz U, Ochsenkühn T, Radke M, Reich K, Rudwaleit M, Schreiber S. “TRECID”, TNFalpha related chronic inflammatory diseases – a new multiple diseases bridging concept. Dtsch Med Wochenschr 2009; 134: 2132-2136.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Ormerod AD, Thomas KS, Craig FE, Mitchell E, Greenlaw N, Norrie J, Mason JM, Walton S, Johnston GA, Williams HC. UK Dermatology Clinical Trials Network’s STOP GAP Team. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ 2015; 350: 2958.
    CrossrefPubMedGoogle Scholar
  • 26 Orphanet. www.orpha.net
    Google Scholar
  • 27 Pereira N, Brites MM, Gonçalo M, Tellechea O, Figueiredo A. Pyoderma gangrenosum – a review of 24 cases observed over 10 years. Int J Dermatol 2013; 52: 938-945.
    CrossrefPubMedGoogle Scholar
  • 28 Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: Classification and management. J Am Acad Dermatol 1996; 34: 395-409.
    CrossrefPubMedGoogle Scholar
  • 29 Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005; 53: 273-283.
    CrossrefPubMedGoogle Scholar
  • 30 Schöttler L, Herbig S, Körber A, Schadendorf D, Dissemond J. Schmerzvermeidung durch unterschiedliche Galeniken von Polihexanid-Gelen: Fallbeispiele von Patienten mit Pyoderma gangraenosum. ZfW 2009; 14: 28-31.
    Google Scholar
  • 31 Schwarzkopf A, Dissemond J. Indikation und praktische Durchführung mikrobiologischer Diagnostik bei Patienten mit chronischen Wunden. J Dtsch Dermatol Ges 2015; 13: 203-210.
    CrossrefPubMedGoogle Scholar
  • 32 Su WPD, Davis MDP, Weenig RH, Powell FCO, Perry H. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol 2004; 43: 790-800.
    CrossrefPubMedGoogle Scholar
  • 33 Thomas KS, Ormerod AD, Craig FE, Greenlaw N, Norrie J, Mitchell E, Mason JM, Johnston GA, Wahie S, Williams HC. UK Dermatology Clinical Trials Network’s STOP GAP Team. Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study. J Am Acad Dermatol. (in press).
    Google Scholar
  • 34 Tremezaygues L, Schmaltz R, Vogt T, Reichrath J. Management des Pyoderma gangraenosum. Update zu Klinik, Diagnose und Therapie. Hautarzt 2010; 61: 345-353.
    CrossrefPubMedGoogle Scholar
  • 35 Ursane MA, Appleyard J, Whiteru O. Pyogenic arthritis, pyoderma gangrenosum, acne, suppurative hidradenitis (PA-PASH) syndrome: An atypical presentation of a rare syndrome. Am J Case Rep 2016; 17: 587-591.
    CrossrefPubMedGoogle Scholar
  • 36 Von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 1997; 137: 1000-1005.
    CrossrefPubMedGoogle Scholar
  • 37 Weenig RH, Davis MD, Dahl PR, Su WP. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med 2002; 347: 1412-1418.
    CrossrefPubMedGoogle Scholar